Immuno-Oncology

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

Bradley J. Monk, MD, shares his insight on the potential of immunotherapy in ovarian cancer, as well as what promise it might hold in other gynecologic malignancies.

Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

The FDA has granted an accelerated approval to the PD-L1 inhibitor durvalumab (Imfinzi) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.

Grzegorz S. Nowakowski, MD, discusses the ever-changing landscape of mantle cell lymphoma, the intriguing combinations being studied, and the promise that immunotherapy could hold.

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses the impact of a recent study of chimeric antigen receptor (CAR) T cells in head and neck squamous cell carcinoma.

Stephen M. Ansell, MD, PhD, discusses the potential of immunotherapy agents in lymphoma, ongoing clinical trials, and where this blends in with chimeric antigen receptor (CAR) T-cell therapy.